5-Amino-1MQ is a research chemical, not an FDA-approved drug and not a peptide. No human trials exist, so no human side-effect profile exists. This page explains what that absence means; it is not medical advice.
Overview
The direct answer: nobody knows what 5-Amino-1MQ's side effects are in humans, because it has never been tested in humans. There is no clinical trial, no pharmacovigilance record, and no validated list of "expected" reactions. The only safety observations on record come from mouse experiments lasting days to a couple of months — useful for a research program, nearly useless for predicting what daily capsules do to a person. Absence of reported harm here reflects absence of measurement, not evidence of safety.
What the animal studies observed
For what it is worth, the key mouse studies did not flag overt toxicity:
- In diet-induced obese mice given 20 mg/kg subcutaneously three times daily for 11 days, the authors reported no observable adverse effects alongside the weight and cholesterol changes (Biochemical Pharmacology 2018).
- Aged mice tolerated two months of NNMT-inhibitor treatment while gaining grip strength (Scientific Reports 2024).
Both are short studies designed to measure efficacy, not safety. Rodent tolerability routinely fails to predict human adverse effects — that is precisely what phase 1 trials exist to catch, and 5-Amino-1MQ has never had one.
Theoretical risks of chronic NNMT inhibition
NNMT sits at a busy metabolic intersection: it consumes nicotinamide (the precursor for NAD+) and S-adenosylmethionine (the cell's universal methyl donor). The 2014 Nature study that motivated the field showed NNMT knockdown reshapes methylation of histones, polyamine metabolism, and cellular energy expenditure all at once (Nature 2014). That breadth cuts both ways. Open questions include:
- Whether chronically shifting the methylation balance has off-target effects in tissues beyond fat — the knockdown work targeted both adipose tissue and liver, where NNMT is highly expressed.
- How altered nicotinamide clearance interacts with other NAD+-modulating supplements or drugs — people drawn to this compound often also take NMN, NR, or niacin, a combination no study has examined.
- Whether effects observed in obese or aged mice generalize to metabolically healthy humans at all.
None of these questions has an answer yet, and that is the point: they are the questions a clinical development program would be designed to close, and no such program exists for this molecule.
The exposure problem with oral capsules
A subtle safety point: the published studies injected the compound; consumer products are oral capsules. Human oral bioavailability has never been characterized, so a capsule buyer does not know whether they are getting negligible exposure (a waste of money) or substantial exposure to an untested enzyme inhibitor (an uncontrolled experiment). Both outcomes are plausible; neither is reassuring.
Sourcing, quality, and the honest summary
Material sold as 5-Amino-1MQ is labeled "for research use only" and made without pharmaceutical manufacturing controls, so identity, purity, and contamination are additional unknowns stacked on top of the pharmacology. The honest summary: an interesting mouse-stage molecule whose human risk profile is entirely uncharacterized. That uncertainty — not any specific known harm — is the central safety fact. Context on what the research actually shows is on the benefits page and the research overview.
Sport & Anti-Doping Warning
5-amino-1MQ is a small-molecule NNMT inhibitor marketed in some wellness and physique circles; as an unapproved drug, it falls into the general S0 category of non-approved substances under the World Anti-Doping Code.
- >Background on 5-amino-1MQ as an experimental metabolic agent
- >WADA guidance that non-approved drugs are prohibited under S0
Even when not named explicitly on the Prohibited List, experimental metabolic drugs like 5-amino-1MQ are captured by the S0 'non-approved substance' rule.